Journal
CANCER CELL
Volume 27, Issue 4, Pages 431-433Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2015.03.012
Keywords
-
Categories
Ask authors/readers for more resources
The interaction between menin and oncogenic mixed lineage leukemia (MLL) fusion proteins is required for leukemic transformation and may represent a therapeutic opportunity. In this issue of Cancer Cell, Borkin and colleagues describe the development of highly potent small-molecule inhibitors of this interaction that reverse the leukemic phenotype and prolong survival in murine models of MLL-rearranged leukemia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
